To enable NKG2DL-independent tumor recognition, NKAR-NK-92 and NKAR_RD-IL15-NK-92 cells were applied in combination with NKAB-ErbB2 or a novel bispecific antibody termed NKAB-EGFR. This evidence concerns the gene ERBB2 and neoplasm.